Search

Policy on double awarding

We want to support as many young investigators and clinicians as possible in their career development. For this reason, we do not allow ‘double awarding.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Highlights from the SWG

EHA2023 CongressThe EHA2023 Congress was held in Frankfurt, Germany, in June 2023. Guideline sessionTitle‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Read more

Social Media Learning

EHA presents our own microlearning in 4 formats, covering diagnosis, pathology, clinical schemas, and clinical cases within topics in the European Hematology Curriculum.

Read more

Belgium shares EU health priorities for Council Presidency

On December 8, Belgium held a conference to unveil its program for the upcoming Council of the EU Presidency (website), to start on January 1, 2024.

Read more

Release of the First Handbook on CAR-T Cells in Europe

Barcelona, 9, February, 2022 – The EBMT and EHA are proud to announce the release of the first-ever open-access book on CAR-T cells to be officially launched during the EBMT-EHA 4th European CAR-T Cell Meeting (Feb 10-12, 2022, Virtual).

Read more